Recently, flunitrazepam (Rohypnol ~) has become an increasingly popular drug of abuse among young adults, who take it for its euphoric effects. In other cases, the drug has been used by rapists for its sedative and hypnotic effects that can induce a catatonialike trance and memory loss in potential victims; as a result, it has been nicknamed the "date-rape drug". For these reasons, the Drug Enforcemenl Administration recently considered adding the drug (a.k.a. '~Roofies") to the same category as heroin and LSD. A selective and sensitive technique has been developed for extracting, detecting, and identifying flunitrazepam and its two major metabolites (7-aminoflunitrazepam and N-desmethylflunilrazepam) in human urine. Using a solid-phase extraction cartridge containing a Umixed.mode, bonded silica gel (Bond Elut Certify| flunitrazepam and its metabolites were selectively isolated from other urine components and quantitated and identified by gas chromatography-tandem mass spectrometry with a benchtop ion mass spectrometer. The extraction method is rapid, reproducible, and precise, and it has a broad linear working range. The overall extraction e~ciency was found to be more than 90% for the parent drug as well as the two major metabolites.
Introduction
The U.S. Drug Enforcement Agency (DEA) recently considered adding the date-rape drug, flunitrazepam to its list of Schedule 1 narcotics (1) . According to a recent DEA study, the drug, which is also known by the slang name roofies, meets all the requirements for inclusion in the same category as other dangerous and highly restricted drugs such as heroin, cocaine, and LSD (1, 2) . The action was considered in response to the recent dramatic increase in the smuggling, trafficking, possession, and overall abuse of the powerful hypnotic, which produces a prolonged sedation, a feeling of well-being and short-term memory loss (1) (2) (3) .
Fiunitrazepam, chemical name 5-(2-fluorophenyl)-l,3-dihydro-l-methyl-7-nitro-2H-1,4-benzodiazepin-2-one, is also known by several slang/street names including roofies, rophies, rophynol, ruffles, roche, roach, reyna, the date-rape drug, and the forget pill (1-3).
Although flunitrazeparn is not approved by the FDA for use in the U.S., it is prescribed widely in 64 other countries for insomnia and as a pre-operative anesthetic. In addition, the drug has a good reputation for being both safe and effective when taken under the supervision of a physician, with worldwide sales of more than 2.3 million doses a day. However, in the U.S., nonprescription abuse of flunitrazepam has increased at an alarming rate during the last several years, particularly among young adults who use it at parties, night clubs, and rave dances for its ability to induce a euphoric, drunklike high (1, 2) . Even more alarming is the fact that the drug has now become a favorite tool of rapists, who spike it into the drinks of unsuspecting victims who may become catatonic, unconscious, or hypnotized and suffer severe memory loss (1) (2) (3) .
As a result of these problems, law-enforcement officials and drug-testing laboratories are increasingly interested in finding rapid, reproducible, and economical methods for the identification and confirmation of flunitrazepam and its major metabolites in the urine of rape victims and drug abusers (2, 3) . This is a particular dilemma in light of the fact that traditional analytical and extraction methods that were developed for other benzodiazepines are less effective with flunitrazepam and its metabolites, particularly because the parent drug is ten times more potent than other common benzodiazepines such as diazepam, and consequently, present at a lower concentration within the urine (2, 3) .
The current investigation focuses on the development of a rapid solid-phase extraction (SPE) method for the capture and concentration of flunitrazepam and its metabolites from human urine and their subsequent analysis by gas chromatographymass spectrometry (GC-MS) or gas chromatography-tandem mass spectrometry (GC--MS--MS).
(Bohemia, NY). A Reacti Therm TM and a Reacti Vap TM evaporator were purchased from Pierce (Rockford, IL).
Reagents and chemicals
Flunitrazepam, 7-aminoflunitrazepam, N-desmethylflunitrazepam, and alphenal (internal standard) were purchased from Radian Corp. (Austin, TX). Potassium hydroxide and potassium phosphate (monobasic) were purchased from Aldrich (Milwaukee, WI). Phosphoric acid and ammonium hydroxide (30%) were purchased from J.T. Baker (Phillipsburg, N J). GCgrade methanol, methylene chloride, isopropyl alcohol, and acetic acid were purchased from Fischer Scientific (Pittsburgh, PA).
Equipment
A Saturn 4D ion trap GC-MS system (Varian Chromatography Systems, Walnut Creek, CA) equipped with a Wave-Board was used for all experiments. The GC system was equipped with a Septum-equipped Programmable Injector (SPI) and a DB-5 capillary column (30 m • 0.25-mm i.d., 0.25-1Jm film thickness, J&W Scientific, Folsom, CA). The oven temperature was programmed from 100~ increased at a rate of 25~ and held at 280~ for 9.8 rain. The injector was set at 40~ held there for 0.1 min, increased at a rate of 180~ and held at 280~ for 15.57 rain. Helium was used as carrier gas at a linear velocity of approximately 35 cm/s. The transfer line was set held at 260~ and the ion trap manifold was set at 200~ The ion trap MS was tuned via Saturn's autotune program. For MS mode, full scan spectral acquisition was run at 1 scan per second and begun at m/z 50 to m/z 450. The following ions were monitored (quantitation ions are bold): flunitrazepam 286, 285, and 312; 7-aminoflunitrazepam 283 and 254, 255; Ndesmethylflunitrazepam 298, 299 and 252. For MS-MS mode, mass range was set from m/z 200 to m/z 350, nonresonant excitation was used for collision-induced dissociation (CID) and an excitation amplitude of 27 volts was applied.
Specimen preparation
~o milliliters of urine (with or without the spiked standards) and 2 mL of 0.1M potassium phosphate buffer (pH 6.0) were added to a large test tube and the mixture was vortex mixed; the pH was determined and adjusted to pH 4.5-6.5 with either 0.1M H3PO4 or 0.1M KOH, if necessary.
Extraction
Bond Elut Certify columns were connected to a Vac Elut manifold and conditioned with 2 mL of methanol, followed by 2 mL of 0.1M potassium phosphate buffer (pH 6.0). The urine specimen containing flunitrazepam and its metabolites was applied to the column and passed through the bed at a slow flow rate by applying vacuum (2-3 in. of Hg). The column was washed sequentially with 3 mL of deionized water and 1 mL of 1M acetic acid, and the sorbent was dried for 15 min under full vacuum. The column was further washed with 1 mL of methanol and dried under full vacuum for 1 rain. All washes were discarded.
The tips of the Vac Elut delivery needles were wiped clean, and a rack with labeled collection tubes was placed in the Vac
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Journal of Analytical Toxicology, Vol. 24, January/February 2000 Elut. Flunitrazepam and its metabolites were eluted simultaneously using 2 mL of a mixture of methylene chloride/isopmpyl alcohol (80:20) containing 2% of a 30% aqueous solution of ammonium hydroxide. The Vac Elut was disassembled, and the labeled test tubes were removed and placed in the Reacti Therm evaporator and evaporated to dryness under a slow stream of nitrogen at room temperature. One hundred microliters of an alphenal (IS) solution (5 ng/laL in methanol) was added to the tube and vortex mixed, and 1 laL was injected into the GC-MS for analysis. The traditional procedure, which was developed by Varian scientists, for the extraction of benzodiazepines was conducted as described (4, 5) .
Results and Discussion

Metabolism and analysis
Flunitrazepam is biotransformed in humans through a variety of metabolic pathways; these include N-desmethylafion, 3-hydroxylation and subsequent glucuronidation, and the reduction of the nitro group to an amine which can then be acetylated ( Figure 1 ). Various combinations of these reactions are also possible (3, 6) . Although over a dozen different final metabolites may appear in the urine, the latter pathway appears to be preferred, with over 10% of the administered close being excreted as 7-arninoflunitrazepam (3, 6) . In contrast, less than 0.2% of the native, unmetabolized drug is excreted in the urine (3, 6) . The average half-life of flunitrazepam in human urine is 19 h, and within a week, an average of 84% of a radiolabeled dose is typically eliminated in the urine (3, (6) (7) (8) .
A variety of analytical methods have been developed for the detection of flunitrazepam and its metabolites. GC with electron-capture detection (ECD) have been used to quantitate the drug and its desmethyl metabolite, either with (9,10) or without (11, 12) acid hydrolysis. Liquid chromatographic methods have also been developed for flunitrazepam and its metabolites, and these have made use of either 1N or fluorescence detection techniques (13, 14) . However, the sensitivity of these methods is low (9) (10) (11) (12) (13) (14) , and it is generally recognized (2) that GC--MS is required in order to detect these compounds at the trace concentrations which are found in typical urine samples (50-400 ng/mL urine). This is due to the drug's therapeutic potency and low dosage requirements (1 or 2 mg), multiple metabolic pathways, and relatively long half-life in vivo (1) (2) (3) 6) . Calculations based on all of these factors (and taking into account the low dose requirements in conjunction with the multiple metabolic pathways, long half-life and assumptions about typical urinary output volume) indicated that even the major flunitrazepam metabolite (7-aminoflunitrazepam) is expected to be present at concentrations as low as 100 ng/mL urine following a single prescription dose.
In fact, neither flunitrazepam nor its metabolites can be detected by EMIT or other similar immunoassays, so it will not be detected in DUF or DAWN (2) . Although there are other commercially available antibody-based test kits that have been shown to be able to detect moderately low levels of the drug, these are generally unable to detect 7-aminoflunitrazepam at concentrations below 120 ng/mL of urine and typically fail to give a positive response in subjects given a 1-mg dose of the parent drug (15, 16) .
As a result of the apparent limitations of conventional analytical methods for the detection of flunitrazepam and its metabolites in human urine, an investigation was recently conducted in our laboratories in an attempt to develop a more sensitive, state-of-the-art method based on SPE coupled with GC-MS (17, 18) . That method is the subject of this paper.
Bond Elut Certify
Bond Elut Certify is a mixed-bed chromatographic support containing a mixture of short alkyl chains and strong cation exchange moieties that was specially designed for the SPE of drugs of abuse (5, 19, 20) . For benzodiazepines and their major metabolites, the extraction procedure relies on a mixed-mode etention mechanism that consists of hydrophobic interactions etween the alkyl chains on the sorbent and the lipophilic, hydrocarbonaceous backbone of the benzodiazepine molecules, in Combination with a cation exchange mechanism between the sulfonic acid groups of the sorbent and the amines on the drugs and their metabolites (5, 19, 20) .
The Certify was developed over eight years ago, and since that time it has been used in numerous clinical and forensic laboratories for drug screening purposes and in academic studies that were focused on the metabolism and pharmacokinetics of benzodiazepines as well as a number of other drug compounds (21-.43) .
Many studies (5, have shown that the mixed-mode interactions and unique surface chemistry of the Certify, in combination with the application-specific extraction methods that have been developed for individual drugs or drugs classes, often provide an extraction that is both highly specific and efficient, such that the extracted sample is extremely clean and virtually free of interfering compounds with an excellent sample-tosample reproducibility and high recoveries for the compound(s) of interest.
SPE method optimization
Our original attempts to efficiently extract flunitrazepam and its two major metabolites (7-aminoflunitrazepam and Ndesmethylflunitrazepam) with the "generic" Certify method that had previously been developed for other benzodiazepines (4) were unsuccessful. According to this procedure, the urine sample (see Specimen preparation section) is loaded onto the column (see Extraction section for column conditioning) and washed sequentially with 0.1M phosphate buffer (pH 6)/methanol (8:2), 1.0M acetic acid, and hexane. Next, the column is dried for 2 rain under full vacuum, and the drugs are eluted with neat methylene chloride (4, 5) . However, attempts to use this procedure for the extraction of flunitrazepam and its metabolites provides recoveries of less than 50%, and the extracts are dirty.
'l~oubleshooting experiments indicated that these low recoveries were related to the use of phosphate-buffered methanol in the first wash step, which was simultaneously able to partially disrupt the ionic and the hydrophobic interactions between the sorbent and the analytes. Improved final recoveries were obtained when the polarity of this mixture was increased by reducing the methanol concentration to less than 10% or by eliminating it altogether. In fact, in the final, optimized procedure, the phosphate buffer/methanol was replaced with deionized water. Under these wash conditions, none of the analytes were eluted prematurely and the recoveries were almost quantitative (Table I) .
In a second set of optimization experiments, it was shown that the second wash step in the traditional extraction procedure for benzodiazepines, which uses acetic acid, had no deleterious effects on the recovery of the flunitrazepam or its metabolites and was, in fact, able to remove a variety of contaminating compound. As a result, this step was not modified (18) .
Subsequent experiments indicated that the third and final wash step with hexane provided poor baseline cleanliness; this is presumably related to the extreme nonpolar nature of this solvent and its ability to drive even slightly polar interferences i A i onto the sorbent. Replacement of the hexane in the original procedure with a more polar solvent, such as methanol, was shown to reduce these secondary polar interactions, and consequently, minimize the retention of these contaminants on the column (18) . Final method development experiments were conducted in an attempt to optimize the elution conditions, because the original elution solvent (neat methylene chloride) still did not provide quantitative recoveries of the analytes of interest. The best results were obtained with an elution solvent which consisted of a mixture of methylene chloride/isopropanol (80:20) containing 2% of a 30% aqueous solution of ammonium hydroxide (17, 18) .
Under these optimized conditions, the recoveries of flunitrazepam and its two major metabolites were increased to 90% (17, 18) . Table I provides recoveries of flunitrazepam and its metabolites in spiked urine at concentrations of 50, 125, and 500 ng per milliliter urine. Figure 2 illustrates the linearity of the recovery of 7-aminoflunitrazepam following extractions on Certify with this optimized method in which urine samples were spiked with 7-aminoflunitrazepam over a concentration range ~om 0 to 1200 ng/2 mL. The peak-area ratios of the analyte (m/z 283) and the internal standard (m/z 215) were plotted against the corresponding concentration, and the correlation coefficient was excellent, at 0.9967.
The combined effects of the optimization of the two wash steps and the elution step show the improvements in the extraction efficiency obtained in terms of baseline noise/ chromatographic cleanliness and recovery. Prior to our method-development experiments, the recoveries were low (50%) and there were a number of interferences that eluted closely to (or coeluted with) flunitrazepam and its metabolites. Following method optimization, the recoveries were high (Table I) .j~ E Figure 4 . GC--MS analysis of five different urine samples from suspected date-rape victims in which flunitrazepam was implicated. Samples ^ and B were found to contain 7-aminoflunitrazepam at concentrations of 472 and 308 ng/mL, but samples C-E contained undetectable levels of flunitrazepam and its metabolites (the cursor is set on the re~ntion time for the 7-aminoflunitrazepam).
GC-MS detection
The high extraction efficiency of this optimized SPE method is also illustrated in Figure  3 , which shows the total ion GC trace of an extract of a typical negative urine sample spiked with flunitrazepam and its two major metabolites, each at a concentration of 50 ng/mL urine ( Figure 3A) relative to the blank urine ( Figure 3B ). The total ion peak areas of the interfering compounds which are observed in this typical blank urine is less than 0.5% of the area obtained at the same retention times in the spiked sample, suggesting that even without MS analysis and specific-ion-based quantitation methods, concentrations as low as 4 ng/mL of urine could be detected with an acceptable signal-to-noise ratio of 4. Similar limit of detection (LOD) values for 7-aminoflunitrazepam (5 ng/mL) have been reported (15, 16) with other GC-M8 techniques following sample preparation with liquid-liquid extraction methods; however, these methods required sample hydrolysis and derivatization.
The ability to detect low levels of 7-aminoflunitrazepam in most urine specimens with GC-MS is also illustrated in Figure  3 which shows the relative total ion peak areas obtained with a particularly dirty (interference laden) urine sample which was extracted and analyzed, either as a neat sample ( Figure 3B ) or following fortification with 50 ng/mL ( Figure 3A) . Even with this dirty sample, the LOD is still 20 ng/mL, which is probably adequate for the detection of the metabolite in the majority of samples. This view is also supported by the relative clean baselines and the lack of contaminants that might potentially interfere with 7-aminoflunitrazepam in the vast majority of the 18 negative samples that we have analyzed; some of these are shown in Figure 4 . However, in other instances (as will be demonstrated), it is clear that only GC-MS or GC-MS-MS can provide an absolute confirmation of the presence of 7-aminoflunitrazepam in urine specimens.
According to calculations based on the available metabolic data, the lowest single prescription dosage of flunitrazepam (1 rag) would be expected to produce a urinary concentration of at least 50 ng of 7-aminoflunitrazepam per milliliter for more than an entire day after administration/ingestion. Phar- macokinetic studies conducted by the manufacturer (3, 15, 16) support this contention, with a 2-rag dose providing peak urinary values of 200 ng/mL of the metabolite after 12 h. Higher doses such as those used for purposes of intoxication or date rape would be expected to produce considerably higher concentrations of 7-aminoflunitrazepam. In fact, several authentic samples that were analyzed with our method were shown to contain the metabolite at concentrations between 300 and 500 ng per milliliter of urine ( Figures 4A and 4B and Table II ). These concentrations are almost two orders of magnitude above the minimum detection limit (limit of detection) that can be obtained with conventional GC detection methods alone (in the absence of MS or MS-MS analysis) in the absence of excessive levels of interfering/coeluted urinary compounds.
GC-MS detection sensitivity
However, the ability to use GC-MS to quantitate at the mass numbers which are characteristic of the individual analytes increases the sensitivity which can be achieved with GC-MS detection method by a considerable degree, and most importantly, increases the reliability of the method in terms of obtaining a positive identification and confirmation of the drug or its metabolites or both, particularly in the presence of high levels of contaminants (Figures 3-5 ).
The power of this 8PE technique when coupled to GC-MS is illustrated in Figure 5 , which shows the use of these methods to confirm the presence of 7-aminoflunitrazepam in a urine sample provided by the forensics laboratory of a local law-enforcement agency. This method is equally effective for confirming the absence of flunitrazepam and its metabolites in negative urine samples. Figure 4 illustrates the use of SPE in conjunction with GC-MS to verify the absence of detectable levels of 7-aminoflunitrazepam (or other flunitrazepam metabolites) in 18 out of 20 urine samples from date-rape cases in which flunitrazepam were implicated. Although two samples were found to contain 7-aminoflunitrazepam ( Figures 4A and 4B) , the remaining specimens (some of which are shown in Figures 4C-4E ) contained undetectable levels of 7-aminoflunitrazepam and other flunitrazepam metabolites. This, despite the fact that other, less specific analytical methods suggested that 11 of the 18 samples did, in fact, contain benzodiazepines, or more specifically, flunitrazepam or its metabolites or both. The negative results obtained by our method were corroborated by another group (15, 16) that had analyzed these samples by GC-MS following a liquid-liquid extraction procedure. Although both GC-MS analyses indicated that there was, in fact, no evidence of flunitrazepam metabolites in any of these samples, other drugs (cocaine, opiates, and/or other benzodiazepines) were found in most of these specimens.
GC-MS-MS confirmation
More recent developments in ion trap (MS) 2 technology enable us to selectively store and manipulate ions. The parent ion of 7-aminoflunitrazepam 283 can be completely isolated by two-step process: the first step ejects the ions with masses below the parent ion 283, and the second step ejects all masses above the parent ion mass. Then the parent ion 283 constantly undergoes collisions with helium gas in the ion trap. When the parent ion 283 acquires enough vibrational energy, one or more chemical bonds in the ion may be broken, forming ions of lower m/z 255 than the original 283. The ions that are formed from this collisionally induced dissociation are called daughter or product ions and their masses are directly related to the chemical structure and mass of the parent ion or precursor ion ( Figure 6 ). In this study, where significant matrix or background interference exists, the signal-to-noise ratio was improved more than 17-fold by using MS-MS technique (Figure 7) , and this can open the door to an entirely new dimension in drug detection and confirmation. Figures 8A and 8B illustrate the use of this GC-MS-MS technique (as described) to confirm the presence of 7-aminoflunitrazepam in two authentic samples from other date-rape cases. Clearly, this SPE-GC-MS-MS method provides strong, essentially unequivocal evidence for the presence of the metabolite in these urine samples, which were also confirmed as being positive by several other techniques (15, 16) .
Hydrolysis and derivatization
Finally, it should be noted that the analytical and extraction procedures used in this investigation were considerably simpler than other procedures for flunitrazepam, because they do not make use of a acid-based or enzyme-based hydrolysis step or a derivatization step. In a related study (15) , it was shown that the hydrolysis of urine specimens with [3-glucuronidase was able to increase the number of free flunitrazepam metabolites that are available for quantitation, but only by 20-60%. Acid hydrolysis of urine specimens has also been used (16) to convert flunitrazepam and its metabolites into benzophenone derivatives, providing an LOD of 5 ng/mL. However, the results of the current investigation indicate that hydrolysis steps are unnecessary (17, 18) . Table II illustrates the effect of the hydrolysis step on the recovery of 7aminoflunitrazepam from five different authentic positive samples that were obtained from a local law-enforcement agency. In this study, 2 mL of authentic positive sample was hydrolyzed by adding 1 mL of ~-glucuronidase solution contains 5000 F units/mL of Patella vulgata in 0.1M phosphate buffer (pH 6.0) and incubating at 65~ for 3 h. A slight (10%) increase in the metabolite concentration was observed following the hydrolysis of one sample. However, for the remaining samples, the concentration of detectable 7-aminoflunitrazepam either remained constant or actually decreased following the hydrolysis step when compared with side-by-side extractions of the same samples that were conducted without the hydrolysis step (Table  II) . Figure 9 illustrated the total ion chromatograms of a reallife sample extracted with Certify procedure for flunitrazepam. The recovery of 7-aminoflunitrazepam in the sample is equivalent with or without hydrolysis step; however, the chromatogram is cleaner with unhydrolyzed sample (Figure 9 ). In other words, the optimized procedure provided in the Materials and Methods section (in which the hydrolysis step is omitted) provides recoveries that are typically better than those obtained after specimen hydrolysis (17, 18) .
Although the exact reason for this anomalous behavior is unknown, it may be related to similar recovery problems observed in our laboratories with other drugs following an acid hydrolysis step.
Finally, attempts to derivatize flunitrazepam and its metabolites (7-aminoflunitrazepam and N-desmethylflunitrazepam) in which the eluant was transferred into a Reacti vial, evaporated under nitrogen to dryness, 50 mL of BSTFA containing 1% TMCS added, capped, and heated at 90~ for 20 rain provided no significant increases in sensitivity, and in some cases, the peak areas obtained following derivatization were smaller and less reproducible (17, 18) because of variations in the derivatization process and the BSTFA reaction efficiency (44) .
This point is also illustrated in Table II , which compares the recoveries obtained with five authentic positive samples following SPE with either the optimized Certify procedure or that of a competitor procedure (see Table III for a competitor's procedure) in which BSTFA is used to derivatize flunitrazepam and its metabolites. Although the Certify procedure provided excellent recoveries (as support by the results obtained several external laboratories), the competitors product provided extremely poor recoveries (Table II and IV) .
